Companies researching Skyrizi (Risankizumab)
Skyrizi (risankizumab) is a humanized monoclonal antibody that inhibits interleukin‑23A and is jointly developed by Boehringer Ingelheim and AbbVie for treating plaque psoriasis.
16
companies
List of companies that research Skyrizi (Risankizumab)
This is sourced from job postings — companies only hire for what they actively use or plan to adopt · how we source this →

Employees60kRevenue$26BPharmaceutical Manufacturing
Skyrizi (Risankizumab)High confidence
Employees288Revenue$25MHospitals and Health Care
Skyrizi (Risankizumab)Low confidence
Employees501Revenue$100MHospitals and Health Care
Skyrizi (Risankizumab)Low confidence
Employees201Revenue$12MHospitals and Health Care
Skyrizi (Risankizumab)Low confidence
Employees354Hospitals and Health Care
Skyrizi (Risankizumab)Low confidence
Employees1kHospitals and Health Care
Skyrizi (Risankizumab)Low confidence
Employees1kMedical Practices
Skyrizi (Risankizumab)Low confidence
Employees231Revenue$23MMedical Practices
Skyrizi (Risankizumab)Low confidence
Employees94Hospitals and Health Care
Skyrizi (Risankizumab)Low confidenceEmployees15Revenue$7MMedical Practices
Skyrizi (Risankizumab)Low confidence
Showing top companies out of 16 that research Skyrizi (Risankizumab). Get the full list on TheirStack.
Frequently asked questions